- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05953935
Efeito da terapia de transferência elétrica capacitiva resistiva em feridas de difícil cicatrização
Efeito da terapia de transferência elétrica capacitiva resistiva na cicatrização de feridas e na expressão de biomarcadores em feridas de difícil cicatrização
Difficult-to-heal wounds present imbalances in cytokine production, increases in MMP expression, high levels of apoptosis, and decreases in the proliferation of cells such as fibroblasts and keratinocytes, which are involved in tissue regeneration. CRET therapy (capacitive resistive electrical transfer therapy) has been shown to generate granulation tissue in in vitro assays. In addition, available clinical case reports and preliminary clinical trial results indicate that CRET can promote the regeneration of acute wounds and DHW (difficult-to-heal wounds).
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Difficult-to-heal wounds present imbalances in cytokine production, increases in MMP expression, high levels of apoptosis, and decreases in the proliferation of cells such as fibroblasts and keratinocytes, which are involved in tissue regeneration. CRET therapy has been shown to be able to generate granulation tissue in in vitro assays. In addition, available clinical case reports and preliminary clinical trial results indicate that CRET can promote acute wound regeneration and CDH.
The working hypothesis is that CRET treatment promotes the healing of CDH through its action in regulating inflammatory and regenerative processes in skin tissue. This non-invasive, cost-effective treatment, devoid of identified adverse effects, and not studied in depth so far in patients with CDH, can thus be placed in the treatment algorithms of CDH with the correct selection of candidate patients.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Maria Luisa Hernández Bule, PhD
- Número de telefone: 913368699
- E-mail: mluisa.hernandez@hrc.es
Estude backup de contato
- Nome: Almudena Cecilia Matilla
- E-mail: almudena.cecilia@salud.madrid.org
Locais de estudo
-
-
Madrid
-
Madrid, Madrid, Espanha, 28034
- Recrutamento
- Hospital Ramón y Cajal
-
Contato:
- Maria Luisa Hernández Bule, PhD
- Número de telefone: 913368699
- E-mail: mluisa.hernandez@hrc.es
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
18 years of age or older
-
Agree to participate in the study and sign the informed consent form.
-
Inpatients or outpatients who can be followed by the research team for the duration of the study
-
Ulcers with a surface area of no less than 0.5 cm2 and of at least 4 weeks' duration (CDH), located on the lower limbs in the case of ulcers of venous etiology or on the foot, in the case of diabetic foot ulcers.
-
For patients with ulcers of venous etiology: ulcers of venous etiology stage 2, 3 4 with diagnosis of chronic venous insufficiency with open wound CEAP IVC C6 according to CEAP classification (38).
-
For patients with diabetic foot ulcers presenting:
- Type 1 and type 2 diabetics with a glycated hemoglobin (HbA1c ≤10% (in a test no longer than 3 months).
- Patients with UPD without PAD or with associated mild or moderate stage PAD (39) according to the criteria of the intersociety consensus for the treatment of peripheral arterial disease (TASC II).
- UPD Grade 1A, 1C, 2A, 2C according to the Texas classification (40).
- Patients who have required previous surgical debridement and 4 weeks have elapsed since such debridement.
-
Comorbidity is defined as the presence of at least one of the following criteria:
- Smoking more than 10 cigarettes per day in the last 6 months.
- Immunosuppression: systemic treatment with high-dose corticosteroids in the previous 3 months, severe active infection in the previous month, presence of systemic or organ-specific autoimmune disease.
- Renal failure with creatinine > 2 mg/dl.
- Respiratory failure with pO2< 90 mm Hg
- Cardiac failure, grade II or higher
- Anemia or nutritional deficit
- Endocrine disruption under medical treatment
- Neuropathy in the affected area or neurological disease.
- Connective tissue diseases
- Mobility impairment
- Presence of microvascular disease
Exclusion Criteria:
- Pregnancy
- Patients with contraindications for CRET treatments (electronic implants, thrombophlebitis).
- Patients with chronic or pathological wounds that required surgical intervention.
- Ulcers with active infection according to IDSA classification in soft tissues or with clinical and/or radiological signs compatible with osteomyelitis.
- Allergies to standard wound treatment.
- Patients presenting severe renal insufficiency (Glomerular filtration rate ≤30 ml/min in analysis performed in the last 3 months).
- Patient who has presented an acute ischemic event (acute myocardial infarction or stroke, in the 3 months prior to inclusion in the study).
- Patients who present an evolving neoplastic condition, treated by radiotherapy, chemotherapy, hormone therapy or immunosuppressants at the current moment.
- Patients treated for a chronic condition requiring the intake of strong systemic corticosteroids doses ≥ 40 mg prednisone).
- Critical non-revascularizable ischemia or TcPO2 < 25mmHg or a digital hallux systolic pressure < 50 mm Hg in diabetic foot ulcers.
- Patients who do not accept to use the prescribed unloading treatment in the case of diabetic foot ulcers.
- In the case of patients with ulcers of venous etiology, the presence of peripheral arterial disease in any of its stages.
- Patients who do not accept the indicated compressive bandage treatment, in the case of ulcers of venous etiology.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Cuidados de suporte
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: A-E group
Treatment with radiofrequency currents of resistive capacitive electrical transfer therapy (CRET) under hyperthermia conditions plus standard clinical treatments, in patients with ulcers of venous etiology. |
Static Monopolar Capacitive Resistive Resistive Radiofrequency Equipment at 448 kHz standard clinical procedures |
|
Experimental: B-E group
Treatment with radiofrequency currents of resistive capacitive electrical transfer therapy (CRET) under hyperthermia conditions plus standard clinical treatments in patients with diabetic foot ulcers. |
Static Monopolar Capacitive Resistive Resistive Radiofrequency Equipment at 448 kHz standard clinical procedures |
|
Experimental: A-C grouop
Treatment with radiofrequency currents of resistive capacitive electrical transfer therapy (CRET) under hyperthermia conditions plus standard clinical treatments in CDH. |
Static Monopolar Capacitive Resistive Resistive Radiofrequency Equipment at 448 kHz standard clinical procedures |
|
Experimental: B-C grouop
Treatment with radiofrequency currents of resistive capacitive electrical transfer therapy (CRET) under subthermal conditions plus standard clinical treatments in CDH. |
Static Monopolar Capacitive Resistive Resistive Radiofrequency Equipment at 448 kHz standard clinical procedures |
|
Experimental: C-C group
Standard clinical treatments established on the basis of the treatment standards of the International Working Group on the Diabetic Foot (IWGDF), in the case of diabetic foot ulcers (2, 3). For ulcers of venous etiology, the treatment standards according to the guidelines of the Spanish Association of Vascular Nursing and Wounds (Asociación Española de Enfermería Vascular y Heridas) will also be applied. |
standard clinical procedures |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Wound dimensions before and after treatments in patients with HDC treated with CRET therapy plus standard treatment versus patients with HDC undergoing standard treatment alone.
Prazo: 18 months
|
Wound dimensions measurement (area, length and width) before and after treatments in patients with HDC treated with CRET therapy plus standard treatment versus patients with HDC undergoing standard treatment alone. |
18 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
General clinical evaluation:
Prazo: 18 months
|
|
18 months
|
|
Wound evaluation:
Prazo: 18 months
|
|
18 months
|
|
Evaluation of biomarkers in peripheral blood of patients with CDH with or without CRET treatment:
Prazo: 18 months
|
Quantification of cytokines and growth factors: IL-1α, IL-1β, TNFα, IFγ. |
18 months
|
|
In primary cultures of fibroblasts isolated from biopsies of CDH patients with or without CRET treatment, assessment of typical CDH biomarkers related to:
Prazo: 18 months
|
|
18 months
|
Colaboradores e Investigadores
Investigadores
- Investigador principal: Maria Luisa Hernández Bule, PhD, IRYCIS. Hospital Universitario Ramón y Cajal. Madrid, Spain.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Outros números de identificação do estudo
- CRET-ÚLCERAS-01
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .